NCT05626439View on ClinicalTrials.gov

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 28, 2022

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Healthy Participants
Interventions
DRUG

Staccato alprazolam

Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.

DRUG

Oral alprazolam

Study participants will receive single dose of oral alprazolam at pre-specified time points.

Trial Locations (1)

21225

Up0104 1001, Baltimore

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY